Form 4: Pacira CFO Executes Planned Stock Option Exercises
Statement of Changes in Beneficial Ownership
Pacira BioSciences CFO Shawn Cross exercised and sold 12,059 shares of common stock under a pre-established 10b5-1 trading plan.
Summary
- CFO Shawn Cross exercised stock options for a total of 12,059 shares of common stock across three dates: April 20, 21, and 22, 2026.
- All shares acquired through option exercises at a strike price of $16.45 were subsequently sold on the same dates.
- Sales were executed at weighted average prices ranging from $25.01 to $25.14 per share.
- Transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard liquidity management by an executive.
Positives
- Transactions were executed under a pre-planned 10b5-1 program, indicating systematic rather than reactive selling.
- The CFO maintains a significant remaining beneficial ownership of 105,341 shares of common stock.
Negatives
- The executive reduced his direct equity stake through the sale of 12,059 shares.
Risks
- Future share price volatility could impact the value of remaining unexercised options and held shares.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that routine 10b5-1 trading plan activity by C-suite executives is standard corporate practice and generally does not signal a change in management sentiment regarding the company's long-term prospects.
Comparison to Industry Standards
- The use of 10b5-1 plans is a standard governance practice for executives in the biotechnology sector to avoid potential conflicts of interest regarding material non-public information.
Stakeholder Impact
- Minimal impact expected as the transactions were conducted via a pre-arranged 10b5-1 plan.
Next Steps
- Continued monitoring of future Form 4 filings for further insider activity.
Key Dates
| Date | Description |
|---|---|
| 06/09/2025 | Adoption date of the Rule 10b5-1 trading plan. |
| 04/20/2026 | Earliest transaction date for option exercise and sale. |
| 04/21/2026 | Second transaction date for option exercise and sale. |
| 04/22/2026 | Final transaction date for option exercise and sale. |
Keywords
Pacira BioSciences, PCRX, Insider Trading, Form 4, CFO, Stock Options, 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.